GlassScriptPhysician profile
Nicholas J Wagner
NPI 1497915565
$2,119.92
in general payments reported to CMS, 2019-2025
24 companies · $588 in 2025
The $588 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $154 · 2021: $111 · 2022: $116 · 2023: $288 · 2024: $643 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $406.44 | 2021-2025 | Qelbree, Qelbree |
| Cranial Technologies, INC | $218.96 | 2019-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $182.41 | 2020-2024 | |
| Collegium Pharmaceutical, INC. | $161.51 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $138.23 | 2019-2022 | |
| Sanofi Pasteur INC. | $136.69 | 2020-2023 | |
| Glaxosmithkline, LLC. | $122.97 | 2022-2025 | Bexsero |
| Corium, LLC | $109.21 | 2022-2025 | Azstarys |
| Vertical Pharmaceuticals, LLC | $80.66 | 2019-2025 | Relexxii |
| Seqirus USA INC | $75.25 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Sobi, INC | $62.64 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $58.59 | 2025 | Daybue |
| Pfizer INC. | $55.04 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $48.85 | 2019-2025 | Enflonsia, Vaxneuvance |
| Tris Pharma INC | $44.44 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $37.47 | 2024 | Ycanth |
| Shire North American Group INC | $33.24 | 2019 | |
| Adlon Therapeutics L.P. | $28.53 | 2020 | |
| Lnhc, INC | $27.94 | 2025 | Zelsuvmi |
| Intrabio INC | $25.10 | 2025 | Aqneursa |
| Kaleo, INC. | $18.76 | 2023 | Auvi-Q |
| Ultragenyx Pharmaceutical INC. | $17.62 | 2024 | Crysvita |
| Neos Therapeutics, LP | $16.31 | 2024 | Cotempla Xr-Odt |
| Phadia US INC. | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.